Lisa Foster-McNulty

Home/Lisa Foster-McNulty

About Lisa Foster-McNulty

This author has not yet filled in any details.
So far Lisa Foster-McNulty has created 51 blog entries.

BG control in Type 1 Diabetes Improves with Fast-Acting Insulin Aspart

By | 2017-05-18T18:17:19+00:00 May 18th, 2017|May 2017 Newsletter|

According to a study published online in Diabetes Care on April 11, fast-acting insulin aspart (faster aspart) improved blood glucose control in patients with Type 1 diabetes, as compared to the conventional formulation of the drug, insulin aspart (IAsp). In the United States, insulin aspart is better known as Novo Nordisk's insulin Novolog. In many other countries, it is known as NovoRapid.

Diabetes Management: Integrated Diabetes Services vs. Clinic based Endocrinologists

By | 2017-05-08T16:40:40+00:00 May 8th, 2017|Thinking Like A Pancreas Blog|

At Integrated Diabetes Services, we have a different setup. Everyone who works at IDS has a personal connection to diabetes. 3 of our clinicians are CDEs who wear insulin pumps and use a CGM, and the 4th is a CDE who is the mother of a child with Type 1.

Are Routine ECG checks Warranted for People With Type 1 Diabetes?

By | 2017-04-19T15:20:12+00:00 April 19th, 2017|April 2017 Newsletter, Diabetes Bites|

Based upon some recent research published in Diabetes Care, if you have Type 1 diabetes, you might want to talk to your primary care provider about having routine electrocardiograms.

Are milder climates better for less frequent severe hypoglycemia?

By | 2017-03-16T16:22:40+00:00 March 16th, 2017|Diabetes Bites, March 2017 Newsletter|

Big news! Tandem announced on March 2, 2017 that they have launched a software update for t:slim insulin pumps purchased prior to April 2015. That's right, it's a software update.

Tandem Diabetes Releases Software Update for Insulin Pump

By | 2017-03-16T16:15:57+00:00 March 16th, 2017|Diabetes Bites, March 2017 Newsletter|

Big news! Tandem announced on March 2, 2017 that they have launched a software update for t:slim insulin pumps purchased prior to April 2015. That's right, it's a software update.

Expecting Mothers: Most cow’s milk formulas do not raise risk of Type 1 Diabetes

By | 2017-02-21T13:59:42+00:00 February 21st, 2017|Diabetes Bites, February 2017 Newsletter|

Cow's milk has been thought to be a possible risk factor for the development of Type 1 diabetes. New research shows that while most cow's milk formulas do not raise the risk, one type of baby formula could be linked to a greater chance of developing Type 1 when given in the first week of life.

Tresiba gains FDA approval for use in children and adolescents

By | 2017-01-23T22:05:53+00:00 January 18th, 2017|Diabetes Bites, January 2017 Newsletter|

Children and adolescents age 1 and up now have another option in basal insulin. On December 19, 2016, Novo Nordisk announced that the FDA approved an expanded indication for Tresiba (insulin degludec injection 100 U/mL, 200 U/mL).

New Lilly program provides discounted insulin pricing

By | 2017-01-18T19:35:00+00:00 January 18th, 2017|Diabetes Bites, January 2017 Newsletter|

If you are paying full retail pricing at the pharmacy for insulin because you do not have insurance, or are in the deductible phase of your high-deductible insurance plan, you may soon be able to get a little relief.

New Hope: Glucagon for the dual hormone artificial pancreas

By | 2017-01-18T19:24:02+00:00 January 18th, 2017|Diabetes Bites, January 2017 Newsletter|

We are all so eager for a commercially available closed-loop "bionic pancreas" system to hit the market. But glucagon isn't stable for any great length of time after it is reconstituted, so researchers are working on developing a more stable version of it. Read on to learn more about progress on that front!

Encouraging news for Type 1s interested in using a GLP 1 med with insulin

By | 2016-12-16T16:03:15+00:00 December 16th, 2016|December 2016 Newsletter|

We've been seeing more and more research lately on the use of Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs as a treatment adjunct for Type 1, and the news from this latest study is encouraging.